Log In
Print
BCIQ
Print
Print this Print this
 

Nexavar, sorafenib

Also known as: formerly BAY 43-9006

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionInhibitor of CRAF (RAF1) and multiple receptor tyrosine kinases
Molecular Target CRAF (RAF1) ; Vascular endothelial growth factor (VEGF) receptor
Mechanism of ActionRaf inhibitor; FMS-like tyrosine kinase 3 (FLT3) agonist; Platelet derived growth factor receptor (PDGFR) kinase inhibitor; Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117) agonist; Vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) antagonist; Vascular endothelial growth factor (VEGF) receptor 1 (Flt-1) kinase inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$10,560.0M

$10,560.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today